What this means
This is a planned trial that has not started enrolling people or posted results yet. It will test whether the drug Isomyosamine is safe and helps reduce inflammation and muscle loss.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 60–85
- Where
- Not listed
The science
- Registered title
- Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures
- Trial ID
- NCT06942182 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Sarcopenia in Elderly, Frailty, Frailty/Sarcopenia, Frailty in Older Adults
- What is tested
- Isomyosamine 250mg, Placebo 250 mg
- Sponsor
- TNF Pharmaceuticals, Inc.
- Ages
- 60 Years to 85 Years
- Dates
- First posted Apr 24, 2025 · updated Apr 24, 2025
Registry summary
This Phase II clinical study investigates the safety and effectiveness of a new drug, Isomyosamine, in patients with sarcopenia or frailty, conditions associated with aging and muscle weakness. Isomyosamine is a promising oral medication that reduces inflammation by targeting cytokines like TNF-α and IL-6, which are linked to these conditions. Previous studies have shown it is well-tolerated and may help improve muscle strength, mobility, and healing after hip fractures. This trial aims to determine its potential benefits in reducing inflammation and improving recovery in elderly patients.